Get more accurate and reproducible digital pathology analyses for each stage of your drug development process
Identify new insights on pharmacodynamics, mechanism of action, and patient stratification
Accurately quantify biomarkers for patient enrollment, endpoint analysis, and correlative studies in prospective clinical trials
Develop and commercialize AI-powered diagnostics globally and at scale
Our Approach:
AI-based NASH scoring accurately reproduced all study endpoints for NASH resolution and highlighted more granular evidence of reduction in fibrosis
AI-powered PD-L1 scoring identified up to 28% additional PD-L1 positive patients that initially had been classified as PD-L1 negative by manual scoring in a retrospective analysis of a Phase 2b melanoma trial
AI-powered CD8 classification combined with PD-L1 status resulted in 40% increase in biomarker-positive patients vs. biomarker status based on PD-L1 expression alone in a retrospective analysis of a Phase 2b melanoma trial